RECRUITING

Effect of Menthol on ENDS Users' Addiction and Exposure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes, ENDS use exposes users to dependence-producing nicotine and respiratory and cardiovascular toxicants such as aldehydes. Flavor is a major factor in getting young people to use ENDS, thus limiting flavors to menthol and tobacco for prefilled cartridge ENDS "pod mods" was the first major action taken by the FDA to reduce the spread of ENDS among young people. Menthol flavor, however, can present a potential risk given its increasing popularity among young people in the US, and its puffing and nicotine-enhancing properties. Yet, the extent of menthol's ability to affect users' experience and puffing patterns, and how these affect dependence, exposure to toxicants, and clinical outcomes continue to be understudied. Such evidence will be critical to the FDA's ability to set further regulatory standards to reduce ENDS potential harm. The investigators will conduct a 2x2 (pre-post x menthol vs. tobacco flavor) crossover clinical lab study. The investigator will recruit current/past month ENDS users (n=250, 21-35 yrs), who will attend two sessions and use their ENDS once with menthol and once with tobacco flavors. The proposed studies will answer two key regulatory questions consistent with FDA's focus on the role of flavor in tobacco products' addiction and toxicity; 1) compared to tobacco flavor, does menthol carry additional risk by enhancing puffing, abuse liability, and toxicant exposure in ENDS users, and; 2) is this effect more pronounced among high dependence compared to other users. Other outcomes such as harm perception, satisfaction, clinical responses, intention to use or quit, and group comparisons such as according to race, and sex will allow the FDA a comprehensive assessment of the pros and cons of regulating mentholated ENDS for different segments of the society. Such evidence will help advance FDA regulatory policies with the potential to reduce ENDS harm.

Official Title

The Effect of Menthol on ENDS Users' Dependence, Respiratory, and Toxicants Emission Outcomes.

Quick Facts

Study Start:2022-06-22
Study Completion:2027-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05338801

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Generally healthy individuals (determined by physical examination).
  2. * Age of 21-35 years.
  3. * Is willing to provide informed consent.
  4. * Is willing to attend the lab as required by the study protocol.
  5. * E-cigarette users (defined as using e-cigarette either daily or occasionally in the past 30 days)
  6. * Have abstained from e-cigarette use for 12 hours prior to each session
  1. * Report smoking cigarettes regularly (\> 5 cigarettes/month in the past year).
  2. * Report regular use of any other tobacco/nicotine product (e.g., e-cig, pipes, cigars) in the past year.
  3. * Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).
  4. * Individuals with self-reported history of chronic disease or psychiatric conditions.
  5. * Individuals with history of or active cardiovascular disease, low or high blood pressure, seizures, and regular use of prescription medications (other than vitamins or birth control).
  6. * Individuals that report current THC (marijuana) smoking/vaping.
  7. * Individuals that report current EVALI or COVID-19 related symptoms (i.e., cough, shortness of breath, chest pain, nausea, vomiting, abdominal pain, diarrhea, fever, chills, or weight loss)
  8. * Individuals that have or have been exposed to COVID-19 in the last 14 days.

Contacts and Locations

Study Contact

Wasim Maziak, PhD, MD
CONTACT
3053484501
wmaziak@fiu.edu

Principal Investigator

Wasim Maziak, PhD, MD
PRINCIPAL_INVESTIGATOR
Florida International University

Study Locations (Sites)

Florida International University
Miami, Florida, 33199
United States

Collaborators and Investigators

Sponsor: Florida International University

  • Wasim Maziak, PhD, MD, PRINCIPAL_INVESTIGATOR, Florida International University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-22
Study Completion Date2027-03-31

Study Record Updates

Study Start Date2022-06-22
Study Completion Date2027-03-31

Terms related to this study

Keywords Provided by Researchers

  • Menthol Flavor
  • Tobacco Flavor

Additional Relevant MeSH Terms

  • Electronic Cigarette Use